← Markets

BioLife Solutions, Inc.

BLFS · NASDAQ

Market closed$29.15$-1.11 (-3.67%)After hours $29.00 · -0.51%

Key statistics

Previous close$30.26
Open$30.09
Day high$30.88
Day low$28.50
52-week high$30.88
52-week low$17.86
Market cap1.42B
Volume1.37M
Average volume773.96K
P/E ratio-137.92
Forward P/E—
EPS-0.21
Dividend yield0.00%

Market context

Why it moved

BLFS shares declined amid broad selling pressure and bearish technical signals, with the stock pulling back from recent highs as short-term momentum faded and no significant positive catalysts emerged to support the prior price levels.

StockinvestIowadotLovergineIndeedMarketbeat

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026BioLife Solutions fell sharply, pulling back from a 52-week high hit just the prior session, as the stock faces a split valuation narrative — a DCF model suggests ~19.5% upside to a $37.61 intrinsic value estimate, while market multiples at 14.5x P/S signal significant overvaluation versus the Life Sciences industry average of ~4x. The decline comes amid broader risk-off sentiment Friday, with Nasdaq futures pointing notably lower on escalating U.S.-Iran military strikes threatening Strait of Hormuz supply chains and a deteriorating AI spending narrative weighing on growth-oriented names.

-3.6682

July 16, 2026BioLife Solutions surged to a new 52-week high today, with shares advancing nearly 4% on above-average volume as the stock touched $30.31 intraday — a milestone that caps a ~39% gain over the past year and a 20%+ year-to-date run. The rally comes amid a broadly positive session for healthcare, lifted by UnitedHealth's strong Q2 earnings beat and guidance raise, which boosted sentiment across the sector. BioLife's momentum is underpinned by its own strong fundamentals: Q1 2026 revenue of $27.5 million beat estimates by over 7%, with earnings forecast to grow ~50% annually and revenue projected to rise ~18% per year — well above broader market growth rates.

3.8079

July 15, 2026BioLife Solutions closed up nearly 2% in regular trading, outperforming a mixed healthcare sector (XLV roughly flat in after-hours) as investors responded to third-party analysis flagging the stock as potentially undervalued by ~25% relative to intrinsic value estimates, with earnings forecast to grow over 50% annually. The cell and gene therapy biopreservation specialist also drew attention after its recent inclusion in Russell Value Benchmarks, while routine RSU tax-withholding filings from its CFO and EVP were deemed neutral by analysts. In after-hours, shares pulled back modestly, erasing the day's gains.

1.7452

July 15, 2026BioLife Solutions gained nearly 2% in regular trading, outperforming the broader healthcare sector (XLV ended the day lower) as a new analysis flagged the stock as potentially undervalued by ~25% relative to estimated intrinsic value, with earnings forecast to grow over 50% annually and revenue expected to rise 17.7% per year. The company's recent inclusion in multiple Russell Value Benchmarks has added to investor interest, while routine insider RSU tax-withholding filings from the CFO and EVP carried no negative signal. Shares are extending gains modestly in after-hours trading, holding above $28.70.

1.9573

July 10, 2026BioLife Solutions closed essentially flat as investors weigh the company's recent inclusion in multiple Russell value indexes — including the Russell 2000 Value and Russell 3000 Value — against an ongoing fair value debate, with one DCF model pegging intrinsic value at ~$32.44, implying roughly 17% upside. The CGT-focused bioproduction supplier returned to positive net income in Q1 2026 with $27.5M in sales, and analysts forecast ~50% annual earnings growth, though customer concentration risk and execution against full-year revenue guidance remain key investor concerns. The broader healthcare sector (XLV) also drifted lower on the day amid macro uncertainty tied to U.S.-Iran military escalation and rising oil prices.

-0.1771

July 10, 2026BioLife Solutions gained nearly 4% on Thursday, outperforming the flat healthcare sector (XLV essentially unchanged in after-hours) amid renewed investor interest following the company's late-June addition to multiple Russell value indexes, including the Russell 2000 Value and Russell 3000 Value. The index inclusions have broadened institutional visibility for the cell and gene therapy bioproduction company, which returned to positive net income in Q1 2026 with $27.5M in sales, and analysts point to a DCF-derived fair value near $32.44 — roughly 17% above recent trading levels — as a potential upside catalyst. Healthcare has been one of the strongest-performing sectors in recent weeks, adding further tailwind to the move.

3.8249

July 8, 2026BioLife Solutions declined amid a broad risk-off session driven by renewed U.S.-Iran military exchanges that sent oil prices sharply higher and weighed on equities broadly, with the S&P 500 and Nasdaq both pulling back. Adding company-specific context, BioLife's recent addition to multiple Russell value indices in late June — including the Russell 2000 Value and Russell 3000 Value — has raised its institutional visibility, though analysts note the key near-term catalyst remains execution against 2026 revenue guidance, with Q1 2026 sales of $27.5 million and a return to positive net income providing the fundamental backdrop.

-2.6495

July 1, 2026BioLife Solutions closed essentially flat on the regular session but ticked higher in after-hours trade, with the stock up roughly 1.4% in extended trading. The week's storyline has been dominated by two catalysts: reported buyout interest from multiple parties that surfaced June 27 and sent shares surging, followed by the company's simultaneous addition to six Russell Value benchmarks — including the Russell 2000 Value, 3000 Value, and Microcap Value indices. The Russell inclusions are expected to draw passive and value-oriented institutional flows, while the M&A speculation adds a takeover premium. Underpinning the narrative, BioLife beat Q1 2026 revenue estimates ($27.5M vs. $25.7M expected) and reiterated full-year guidance, reinforcing its recovery in the cell and gene therapy supply chain. Volume today ran well above average (~1.2M vs. 690K avg), reflecting continued investor attention. Analysts peg a fair-value target near $32, roughly 13% above current levels.

-0.212

Simply Wall Street · July 7, 2026How Broad Russell Value Index Inclusion Will Impact BioLife Solutions (BLFS) InvestorsBloomberg.com · June 26, 2026Biolife Is Said to Have Drawn Takeover Interest From RepligenThe Business Journals · June 24, 2026BioLife Solutions opens specialized Bothell lab in former churchPR Newswire · May 7, 2026BioLife Solutions Reports First Quarter 2026 Financial ResultsPR Newswire · April 21, 2026BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCasePR Newswire · February 26, 2026BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations
Mt Newswire · May 7, 2026Earnings Flash (BLFS) BioLife Solutions, Inc. Reports Q1 Revenue $27.5M, vs. FactSet Est of $25.7M
Benzinga · February 26, 2026BioLife Solutions Earnings Report: Q4 Overview
Benzinga · February 26, 2026BioLife Solutions Sees FY2026 Sales $112.500M-$115.000M vs $111.058M Est.
Benzinga · February 26, 2026BioLife Solns Q4 Adj. EPS $0.04 Beats $(0.02) Estimate, Sales $24.764M Beat $24.082M Estimate.
Mt Newswire · February 26, 2026Earnings Flash (BLFS) BioLife Solutions, Inc. Reports Q4 Revenue $24.8M, vs. FactSet Est of $24.1M
Mt Newswire · February 12, 2026BioLife Solutions Signs Multi-Year Supply Deal with Qkine
Mt Newswire · January 12, 2026BioLife Solutions Reports Preliminary Q4 Revenue
Benzinga · November 24, 2025HC Wainwright & Co. Reiterates Buy on BioLife Solutions, Maintains $32 Price Target

Peers

S&P 500SPX · $7,457.69-1.01%LivaNova PLCLIVN · $80.70-1.33%Envista Holdings CorpNVST · $26.74-0.93%iRhythm Technologies, Inc.IRTC · $110.88-3.88%Fortrea Holdings Inc.FTRE · $17.76-0.89%Azenta, Inc.AZTA · $26.29-1.83%Personalis, Inc.PSNL · $15.39-1.22%Alamar Biosciences, Inc.ALMR · $25.95+4.01%ADMA Biologics, Inc.ADMA · $8.71-1.14%Repligen CorporationRGEN · $147.25-0.88%Cryoport, Inc.CYRX · $16.51+0.12%Arcturus Therapeutics Holdings Inc.ARCT · $6.05-2.10%